have been developed or are currently under investigation, conducted a prospective trial designed to improve the comsuch as the use of high-dose cytosine arabinoside, 3 
therapy-related AML (tAML). Thirty-four patients (median age
Although the use of ID or HD cytarabine has been widely determined. In a randomized study of refractory or relapsed (100 mg/m 2 of body-surface area per day as a continuous infusion for 7 days), followed by G-CSF until neutrophil recov-AML patients, the German Cooperative Group failed to demery or treatment failure. Nineteen patients (56%, 13/24 in the ID onstrate a higher CR rate with increasing dosage of cytarabine, group and 6/10 in the SD group) achieved a CR (14/25 sAML as the increased antileukemic efficacy of the higher doses was and 5/9 tAML). Early death occurred in four patients, but four cancelled by a higher rate of toxic deaths. 18 Despite these additional patients died in CR from treatment-related toxicity uncertainties, two ongoing studies of intensive therapy of (overall toxic death rate 24% enhanced in some way the antileukemic effect of chemoKeywords: secondary AML; therapy-related AML; idarubicin; Gtherapy. Interestingly, this benefit was mainly observed in CSF; PBSC transplantation patients with unfavorable cytogenetic abnormalities known to be associated with prior MDS. 21-23 A similar result was reported in a non-randomized study from the MD Anderson Introduction group using G-CSF in AML and MDS patients. 15 More recently, in two preliminary reports of randomized trials of Despite a better understanding of the biology and the natural G-CSF after chemotherapy in bad-risk MDS patients by the history of primary myelodysplastic syndromes (MDS), the best HOVON group 24 and in AML patients by Link et al 25 patients approach in the treatment of MDS patients is still to be treated with chemotherapy and G-CSF had an increased CR defined, especially of those who develop secondary acute rate over controls, although the difference has not yet reached myelogenous leukemia (sAML). For instance, the benefits of intensive therapy in sAML patients remain controversial, statistical significance. However, two large trials failed to in view of the usually low complete remission (CR) rates demonstrate a benefit of the G-CSF administration on the CR and CR durations obtained using AML-type intensive chemorate when used during the induction treatment of AML therapy. [1] [2] [3] [4] [5] Similarly, patients with therapy-related AML patients. 26, 27 (tAML) chespond poorly to AML-type intensive regimens. 6 Consequently, we decided systematically to include This question, however, is of clinical importance for younger patients with sAML or tAML with a good performance status patients, since efficient alternatives to intensive chemotherapy in a prospective phase II trial designed to improve the CR rate are not currently avaialable. [7] [8] [9] [10] [11] Furthermore, the induction of using a combination of intensive AML-type chemotherapy and complete remission prior to allogeneic bone marrow trans-G-CSF. We used ID cytarabine in the induction regimen of plantation appears to prolong disease-free survival in younger patients aged less than 65 years but recommend the use of patients with an HLA-compatible sibling. 12, 13 SD cytarabine in continuous infusion to treat older patients in In order to improve the results of intensive induction therthis pilot study. apy in high-risk MDS or sAML patients, several approaches
As a secondary objective, we assessed the feasibility of autologous peripheral blood stem cell (PBSC) transplantation as intensive post-remission therapy in younger patients who four patients.
Materials and methods
(2.0 Gy twice per day on days −8, −7 and −6) and cyclophosphamide (60 mg/kg of body weight per day on days −4 and −3).
Selection criteria
Patients without a donor were planned to receive an autologous stem cell transplantation after one course of intensive Patients 15 years old or older with either AML secondary to a primary MDS, documented by examination of both peripheral consolidation chemotherapy (idarubicin at 12 mg/m 2 of bodysurface area per day for 2 or 3 days and ID cytarabine at blood and bone marrow specimens for more than 3 months, or tAML following a previous malignancy treated with radi-1 g/m 2 of body-surface area as a 2 h infusion every 12 h for 4 or 5 days), followed by PBSC mobilization by G-CSF adminisation and/or chemotherapy were eligible for enrollment in the study. Patients with AML secondary to occupational exposure tration starting at day 20 and collection by apheresis procedures according to standard techniques. The autologous to potential carcinogens (benzene and derivatives or radiations) were eligible, and classified as tAML patients.
transplant conditioning regimen consisted of cyclophosphamide (60 mg/kg of body weight per day on days −4 and −3), Patients were excluded if they had a Karnofsky performance status lower than 40%, an abnormal left ventricular ejection busulfan (4 mg/kg of body weight per day on days −10 to −7), and etoposide (15 mg/kg of body weight per day on days −6 fraction, prior intensive chemotherapy for AML or prior therapy with colony-stimulating factor or cytokine. MDS and AML and −5). In case of an insufficient harvest of progenitor cells (р2 × 10 6 CD34 + per kilogram of body weight) from periphwere classified according to the French-American-British (FAB) classification. 28, 29 eral blood, autologous bone marrow was collected and used as graft. There was no purging of autologous PBSC or marrow graft. G-CSF was not administered after graft infusion.
Older patients in CR after the SD cytarabine induction 30 Results were classified as 'insufficient patients 65 years old or older with the continuous infusion of cytarabine, but the final assignment of each patient older than metaphases' if only five metaphases or less had been analyzed. The response to therapy was defined using the same 65 years to receive ID or SD cytarabine was left to the physicians in care.
criteria as for newly diagnosed AML. 31 In addition, all included patients must not have any persistent myelodysplasAll patients received G-CSF at a daily dose of 5 mg/kg of body weight as a 30-min intravenous infusion, starting on day tic features in CR, except mild dyserythropoiesis. Therapeutic failures were classified as resistant disease (including partial 9 following the initiation of chemotherapy in patients receiving SD cytarabine and on day 15 in patients receiving ID cytaremission and failure) or death (including early death and death during treatment-induced bone marrow hypoplasia). rabine. A bone marrow aspirate was performed the day before the initiation of G-CSF, but G-CSF was given to all patients regardless of the result of this bone marrow examination. G-CSF was continued until there was evidence of neutrophil Results recovery (absolute neutrophil count Ͼ1000 /mm 3 for 3 consecutive days). G-CSF was discontinued in patients with resistPatients characteristics (Table 1) ant disease or leukemic regrowth.
Bone marrow was assessed after neutrophil recovery or on Between June 1993 and May 1995, 34 consecutive patients from four institutions, with a median age of 61 years (range day 45 (and then every 10 days) in the case of persistent cytopenia, or earlier if circulating leukemic blasts reappeared after 35-73) met all the selection criteria and entered the study. Twenty-one patients had sAML evolving from a refractory anea period of documented neutropenia. Patients who failed to achieve a CR after one course were taken off the study and mia with excess blasts (RAEB). Four patients had sAML evolving from a chronic myelomonocytic leukemia (CMML). Nine offered other therapy.
patients had tAML as they had received previous chemotherapy for breast cancer (two patients), myeloma or plasmocytoma (two patients), non-Hodgkin lymphoma (one patient),
Post-remission therapy and ovarian tumor (one patient), or had a history of occupational exposure to potential carcinogens (three patients). All younger patients in CR after the ID cytarabine induction chemotherapy were assigned to receive intensive post-
The median time between AML diagnosis and initiation of intensive induction chemotherapy was less than 1 month remission therapy.
Patients less than 55 years of age with a major histocompat-(range 1 day to 27 months). Only four patients received lowdose chemotherapy for AML before entering the study (lowibility complex (MHC) compatible related or unrelated donor were assigned to allogenic bone marrow transplantation dose cytarabine in three patients, 6-mercaptopurine, hydroxyurea, and etoposide in one patient). Cytogenetical analysis (BMT) after one to three courses of consolidation chemotherapy (amsacrine at 90 mg/m 2 of body-surface area per day was performed in all but one patient. Twenty-four patients with a median age of 55 years (range for 1 day and cytarabine at 60 mg/m 2 of body-surface area as a subcutaneous infusion every 12 h for 5 days). The allogeneic 37-72) received the ID cytarabine regimen as induction course, while 10 patients with a median age of 67 years (range BMT conditioning regimen consisted of total-body irradiation into CR, while 10/17 patients without residual blasts before tAML patients were 62% and 56%, respectively, while only one of the four post-CMML sAML patients obtained a CR. In contrast, the response to induction therapy differed among 61-73) received the SD cytarabine regimen. Eleven patients subgroups of patients defined by cytogenetics (P = 0.04, by were 65 years old or older. Seven of them were treated with Fisher's test). The CR rate was significantly higher in patients SD cytarabine, while four of them received ID cytarabine.
with a normal diploid karyotype (intermediate cytogenetics) than in those with unfavorable abnormalities (79% vs 37%; P = 0.02, by Fisher's test). These subgroups of patients were
Response to induction therapy (Table 2) certainly too small to further analyze this interaction, but it was interesting to note that the ID cytarabine regimen did not Nineteen patients (56%) achieved a CR. Complete remission seem to benefit patients with unfavorable abnormalities, as a rates were similar in patients treated with ID cytarabine and similar interaction between response to therapy and cytogen-SD cytarabine (54% and 60%, respectively; P = 0.75, by Fishetics was still observed in the 24 patients treated with ID er's test). Four patients (two patients in the ID cytarabine cytarabine (82% vs 25%; P = 0.015, by Fisher's test). group and two patients in the SD cytarabine group) died early Table 2 Response to induction therapy ID patients SD patients All patients (n = 24) (%) (n = 10) (%) (n = 34) (%) Including early death and death during treatment-induced bone marrow hypoplasia.
Intensive post-remission therapy in younger patients cytosine arabinoside, 3 newer drugs such as idarubicin, fludarabine, and growth factors remain to be demonstrated.
3,14,16,24,32-34 These reports often evaluate the result of Thirteen patients with a median age of 55 years (range 37-72) were in CR after the ID cytarabine induction course. Two intensive therapy in heterogenous series of patients with either RAEB, RAEBt, sAML, or tAML and subgroup analysis accordpatients with a post-MDS sAML and a MHC compatible sibling were allografted in first CR. One died after alloBMT. Only ing to diagnosis is often not available. Unfavorable cytogenetics and increasing age are the main known prognostic facsix received the intensive post-remission therapy. One patient died of sepsis during the consolidation. Among the five tors of CR rate and CR duration in these patients. 5, 35, 36 In this prospective study of sAML and tAML patients, remaining patients, three had a successful PBSC collection, but two relapsed before autologous transplantation (Table 3) .
patients with MDS only received an AML-type chemotherapy when their disease evolved into AML. The mean age of One patient had a successful bone marrow harvest after failure of leukapheresis.
patients included is 61 years, higher than the mean age of patients in most previous studies evaluating intensive therapy. Overall, one patient with a tAML and one patient with a post-MDS sAML received an autologous transplant. An Cytogenetical results in these 34 patients are those expected in an unselected high-risk MDS population, with a preponderadditional patient was allografted in early relapse. The planned intensive post-remission therapy was not performed ance of unfavorable karyotypes. Despite these poor prognosis characteristics, results obtained in our cohort of patients are in the seven remaining patients as two died in CR from treatment-related toxicity, two relapsed early, and three had a poor comparable to those reported by others. The role, if any, played by the use of ID cytarabine cannot status or were too advanced in age.
be evaluated due to the very poor outcome of our patients and the small size of this study. Nonetheless, HD cytarabine use in induction of AML patients has been recently shown to
Follow-up be beneficial in patients aged less than 60 years in an Australian study, 37 as in the SWOG study. 38 In these studies, a The median follow-up in the whole population, as well as in the 19 patients in CR, is 19 months (range 13-37 months). Of higher disease-free survival was obtained with HD cytarabine compared to SD, instead CR rates were comparable. Such a the six patients in CR after the SD regimen, four relapsed, and two are alive in CR (12 m + , 15 m + ). Of the 13 patients in CR benefit could be indeed hard to demonstrate in such a highrisk population with a high incidence of unfavorable cytogenafter the ID regimen, only four are alive, including three patients in relapse and one in CR after alloBMT (18 m + ). The etics. Of interest, our results suggest that the poor prognosis associated with unfavorable cytogenetics is apparently three patients still in CR had a post-MDS sAML. The median overall survival is 9 months, without any significant difference unmodified by the use of ID cytarabine. In the CALGB study, the benefit of HD cytarabine as a post-remission therapy, was between ID and SD patient groups. Twenty-eight patients have died (20 of the 24 ID patients and eight of the 10 SD mainly restricted to younger AML patients with normal or so called favorable cytogenetics. 39 Clearly, new modalities of patients). Among these 24 deaths, four occurred during remission induction and four in CR patients. The treatmentpost-remission therapy have to be investigated to prolong CR duration and survival in these patients. As recently shown by related toxic death rate was therefore 24%, and the inductionrelated mortality rate 18%. Twelve CR patients (eight of the De Witte et al, 34 such an improvement might be obtained by treating patients earlier in the course of MDS disease in selec-13 ID patients and four of the six SD patients) relapsed with a median remission duration of 3 months (range 2-14). Six ted cases (younger patients with normal cytogenetics). The beneficial role of G-CSF administration after the compatients (four of the 21 post-RAEB sAML patients, one of the four post-CMML sAML patients, and one of the nine tAML pletion of intensive chemotherapy in our patients remains to be proven. As discussed above, even if comparisons from one patients) remain alive with a median follow-up of 15 months (range [13] [14] [15] [16] [17] [18] [19] .
study to another are difficult, similar high CR rates were observed without the use of growth factors. Moreover, G-CSF therapy does not seem to particularly benefit patients with unfavorable cytogenetics, at odds with our previously reported Discussion results in elderly patients with de novo AML. 20 As usual, further randomized trials are needed to answer definitely The place of intensive AML-type chemotherapy in the management of high-risk MDS and sAML evolving from MDS or that question. tAML remains controversial. Although increasing CR rates have been reported over the years, the role of high doses of References These procedures were not performed due to early relapse.
